Calcimedica to present at the h.c. wainwright 26th annual global investment conference

La jolla, calif. , sept. 3, 2024 /prnewswire/ -- calcimedica inc. ("calcimedica") (nasdaq: calc), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (crac) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that rachel leheny, ph.d.
CALC Ratings Summary
CALC Quant Ranking